CPP
PFE icon

Crow Point Partners’s Pfizer PFE Stock Holding History

Crow Point Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,514
Closed -$48K – 272
2017
Q2 		$48K Sell
1,514
-2,202
-59% -$69.4K 0.01% 198
2017
Q1 		$121K Buy
3,716
+2,631
+242% +$83K 0.02% 169
2016
Q4 		$33K Sell
1,085
-1,478
-58% -$45.1K 0.01% 229
2016
Q3 		$81K Buy
+2,563
New +$85.7K 0.01% 222

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Crow Point Partners's PFE Position: Q3 2017 in Review

Crow Point Partners sold out of Pfizer (PFE) in Q3 2017, closing a stake of 1,514 shares — an estimated $48K sold.

Crow Point Partners first reported a position in PFE in Q3 2016 and held it in 4 quarters. The position peaked at $121K in Q1 2017. 2,042 funds tracked by Wall St. Rank hold PFE as of Q3 2017.

  • Crow Point Partners reported no remaining Pfizer position as of Q3 2017 after selling out during the quarter.
  • Crow Point Partners sold 1,514 Pfizer shares in Q3 2017, an estimated $48K.
  • Crow Point Partners first reported a position in Pfizer in Q3 2016 and held it in 4 quarters.
  • Crow Point Partners's Pfizer position peaked at $121K in Q1 2017.
  • 2,042 funds tracked by Wall St. Rank held Pfizer as of Q3 2017.

Based on Crow Point Partners's 13F filing for Q3 2017, filed 5 Oct 2017.